Statera BioPharma Operating Income

Statera BioPharma (STAB) currently reports a operating income of $-31M as of September 2022. That compares with $-12M in the prior-year period — down 165.4% year over year. Use the charts on this page to explore Statera BioPharma's operating income history and peer comparisons.

Statera BioPharma's operating income decreased from $-12M to $-31M — a 165.4% year-over-year decrease (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Statera BioPharma reported $-31M in operating income as of September 2022. That compares with $-12M in the prior-year period — down 165.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-31M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Statera BioPharma, and consider following STAB for alerts when major investors trade the stock.

Statera BioPharma is classified in the Healthcare sector. On operating income, it currently shows $-31M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing STAB with unrelated industries.